A2A Adenosine Receptor Agonists for Diabetic Nephropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating diabetic kidney disease, specifically diabetic nephropathy, are limited, and there is a need for additional therapeutic approaches beyond ACE inhibitors and AT II receptor antagonists, as these can have detrimental effects on some individuals and do not adequately address renal injury and inflammation.
Innovation Solution
Administration of an effective amount of an A2A adenosine receptor agonist, potentially in combination with type IV phosphodiesterase inhibitors, to treat and prevent diabetic nephropathy, leveraging the agonists' documented benefits in experimental models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ACE inhibitors or AT II receptor antagonists are used to control blood pressure in diabetic nephropathy, then blood pressure is reduced and proteinuria decreases, but detrimental effects occur in some patients and renal injury is not adequately addressed
Solution Approach 1:
The patent shifts from using ACE inhibitors or AT II receptor antagonists to using A2A adenosine receptor agonists, changing the pharmacological parameter of the treatment approach. This parameter change allows for blood pressure control and proteinuria reduction while avoiding the detrimental effects associated with conventional therapies, particularly in patients who cannot tolerate ACE inhibitors.
2Stress or pressure
If conventional blood pressure medications are used to manage diabetic nephropathy, then blood pressure control is achieved, but renal injury and inflammation are not adequately treated
Solution Approach 1:
The A2A adenosine receptor agonist provides multi-functional benefits by simultaneously controlling blood pressure, reducing proteinuria, and treating renal injury and inflammation. This universal approach addresses multiple pathological aspects of diabetic nephropathy with a single therapeutic agent, unlike conventional medications that primarily focus on blood pressure control.
3Productivity
If ACE inhibitors are used to reduce proteinuria and slow kidney disease progression, then greater potency is achieved, but monitoring is required due to potential detrimental effects
Solution Approach 1:
The patent positions A2A adenosine receptor agonists as an alternative therapeutic option that can be used particularly in patients who cannot tolerate ACE inhibitors. While the agonists demonstrate potency in reducing proteinuria and slowing disease progression, they offer the advantage of avoiding the monitoring requirements and detrimental effects associated with conventional ACE inhibitor therapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of A2A adenosine receptor agonists, such as ATL146e, demonstrates therapeutic potential by reducing inflammation, minimizing urinary albumin excretion, restoring plasma creatinine levels, and improving endothelial function, thereby providing a novel approach to managing diabetic kidney disease.
Implementation Method 1
Administration of an effective amount of an A2A adenosine receptor agonist... to treat and prevent diabetic nephropathy
Implementation Method 2
The effects of adenosine A2A agonists can be enhanced by type IV phosphodiesterase inhibitors such as, for example, rolipram
Data Source
AI summary
The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor.